Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx Walks Away From Option To Develop S*BIO JAK2 Inhibitors; S*BIO CEO Looks To Chart A New Course

This article was originally published in PharmAsia News

Executive Summary

Although anxious to move forward into Phase III trials, Singapore-based S*BIO announced May 4 that partner Onyx Pharmaceuticals will not exercise its options to develop S*BIO's JAK2 inhibitors SB1518 and SB1578. The Singapore biotech has regained full rights to the janus kinase inhibitors and will now look for a new partner to help move forward in development

You may also be interested in...



Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration

Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.

CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line

The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.

Deals Of The Week: Roche/Illumina, GSK/HGSI, Sanofi/MJFF

After a few months of sometimes-testy back and forth, Illumina seemingly has successfully fended off Roche’s hostile offer. But Roche is unlikely to give up on the sequencing tool maker entirely.

Related Content

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel